



ONBOARDING GUIDE

Getting started with FABHALTA and available support for you and your patients



Doctor and patient portrayals.

INDICATION

FABHALTA is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA

FABHALTA, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

- Complete or update vaccinations for encapsulated bacteria at least 2 weeks prior to the first dose of FABHALTA, unless the risks of delaying therapy with FABHALTA outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor.
- Patients receiving FABHALTA are at increased risk for invasive disease caused by encapsulated bacteria, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious infections and evaluate immediately if infection is suspected.

Because of the risk of serious infections caused by encapsulated bacteria, FABHALTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the FABHALTA REMS.

Please [click here](#) for additional Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and Medication Guide.



GETTING REMS
CERTIFIED

VACCINATION
REQUIREMENTS

SUPPORT

PRESCRIBING
FABHALTA

IMPORTANT SAFETY
INFORMATION

Help your patients start their journey with FABHALTA

Get your patients started on FABHALTA with these 3 steps¹



1 Getting REMS certified to prescribe FABHALTA

Because of the risk of serious infections caused by encapsulated bacteria, you will need to become certified in the **FABHALTA REMS** and fulfill its requirements.

[Click here](#) for more details



2 Complete or update vaccinations before starting treatment with FABHALTA

Complete or update vaccinations for encapsulated bacteria **at least 2 weeks** prior to starting FABHALTA, and readminister during treatment according to the most current ACIP recommendations.

[Click here](#) for more details on how Novartis Patient Support can help



3 Prescribing FABHALTA through a limited network of specialty pharmacies

Once you are ready to prescribe FABHALTA, inform your patient which specialty pharmacy will be dispensing their FABHALTA prescription.

[Click here](#) for more details

Novartis Patient Support™

Novartis Patient Support is a comprehensive program that offers assistance to health care professionals and patients for getting started on FABHALTA. For more information, please [click here](#).

IMPORTANT SAFETY INFORMATION (continued)

CONTRAINDICATIONS

- Patients with serious hypersensitivity to FABHALTA or any of the excipients.
- For initiation in patients with unresolved serious infection caused by encapsulated bacteria, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, or *Haemophilus influenzae* type B.

Please [click here](#) for additional Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and Medication Guide.





Getting REMS certified to prescribe FABHALTA

Because of the risk of serious infections caused by encapsulated bacteria, you will need to become certified in the FABHALTA REMS and fulfill its requirements before you can prescribe FABHALTA.¹

FABHALTA, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including *Streptococcus pneumoniae*, *Neisseria meningitidis* (caused by any serogroup, including nongroupable strains), and *Haemophilus influenzae* type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of FABHALTA is contraindicated in patients with unresolved serious infections caused by encapsulated bacteria.¹

To enroll in the REMS:

After enrollment¹:

Review

the FABHALTA Prescribing Information, Health Care Provider Brochure, Patient Safety Guide, and Patient Safety Card.

Submit

the completed Prescriber Enrollment form to the FABHALTA REMS at www.FABHALTA-REMS.com, or by fax to 1-877-206-3255.

Counsel

patients about the risk of serious infections caused by encapsulated bacteria, the need for vaccinations, and the early signs and symptoms of serious infections.

Provide

patients with REMS educational materials and the Patient Safety Card. Instruct patients to always carry this card with them during treatment and for 2 weeks following the last dose of FABHALTA.

At all times during your patient’s journey, a health care provider should report suspected adverse reactions, including cases of serious bacterial infection, and the patient’s clinical outcomes, to Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For more information, view the full REMS program details and requirements at www.FABHALTA-REMS.com. For any certification questions, contact the REMS Coordinating Center at 1-833-99FABHA.

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS

Serious Infections Caused by Encapsulated Bacteria

- FABHALTA, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including *Streptococcus pneumoniae*, *Neisseria meningitidis* (caused by any serogroup, including non-groupable strains), and *Haemophilus influenzae* type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of FABHALTA is contraindicated in patients with unresolved serious infections caused by encapsulated bacteria.

Please [click here](#) for additional Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and Medication Guide.





Complete or update vaccinations before starting treatment with FABHALTA

FABHALTA, a complement inhibitor, increases a patient's susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria. Comply with the most current ACIP recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor.¹

It is REQUIRED that you vaccinate your patients against¹:



Streptococcus pneumoniae



Neisseria meningitidis
(serogroups A, C, W, Y, and B)

Complete or update vaccination against encapsulated bacteria at least 2 weeks prior to starting FABHALTA, unless the risks of delaying FABHALTA outweigh the risk of developing a serious infection.¹

- If urgent FABHALTA therapy is indicated in a patient who is not up to date with vaccines against encapsulated bacteria, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible. For additional details on antibacterial drug prophylaxis, please see the FABHALTA Prescribing Information, Warnings and Precautions (Section 5.1)

During treatment with FABHALTA¹:

As vaccination does not eliminate the risk of serious encapsulated bacterial infections, closely monitor patients for early signs and symptoms. Inform patients of these signs and symptoms, and instruct patients to seek immediate medical care if they occur.

- Evaluate and treat immediately if infection is suspected, as serious infection may rapidly become life-threatening or fatal if not recognized and treated early. Promptly treat known infections
- Consider interruption of FABHALTA in patients who are receiving treatment for serious infections
- While on therapy, patients are required to be revaccinated as needed

For more information, refer to the most current ACIP guidelines at www.cdc.gov/vaccines/hcp/acip-recs.

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Serious Infections Caused by Encapsulated Bacteria (continued)

- Complete or update vaccination against encapsulated bacteria at least 2 weeks prior to the start of FABHALTA, according to the current ACIP recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with FABHALTA. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information.

Please [click here](#) for additional Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and Medication Guide.





ACIP vaccination recommendations

ACIP recommendations for pneumococcal vaccination in adults (≥19 years of age) with complement deficiencies (2023)²

Vaccine received at any age	REQUIRED VACCINATION WHILE ON FABHALTA				
	PCV20	or	PCV15	and	PPSV23
None/unknown or PCV7 only*	1 dose	or	1 dose	and	1 dose at least 8 weeks later
Prior PPSV23 only*	1 dose at least 1 year since last PPSV23	or	1 dose at least 1 year since last PPSV23		
Prior PCV13 only*	1 dose at least 1 year after PCV13	or			1 dose at least 8 weeks after last PCV13, followed by a second dose at least 5 years later if <65 years [†] at least 8 weeks after last PCV13 if ≥65 years
Prior PCV13* + PPSV23 [‡]	1 dose at least 5 years after the last pneumococcal vaccine	or			1 dose at least 8 weeks after PCV13 and at least 5 years after the first dose of PPSV23 [†]
Prior PCV13* + PPSV23 [§]	1 dose at least 5 years after the last pneumococcal vaccine	or			See note [†]

*Given at any age (≥19 years of age).

[†]Review the pneumococcal vaccine recommendations again for patients turning 65 years of age.

[‡]Not yet received dose at ≥65 years of age, or 1 dose of PPSV23 received between 19 and 64 years of age.

[§]Received at ≥65 years of age, or 2 doses of PPSV23 for individuals between 19 and 64 years of age.

^{||}Using shared decision-making for adults ≥65 years old.

ACIP, Advisory Committee on Immunization Practices; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PCV15, 15-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Serious Infections Caused by Encapsulated Bacteria (continued)

If urgent FABHALTA therapy is indicated in a patient who is not up to date with vaccines against encapsulated bacteria according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible.

Please [click here](#) for additional Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and Medication Guide.





ACIP vaccination recommendations (continued)

ACIP recommendations for meningococcal vaccination in adults with complement deficiencies (2020)³

REQUIRED VACCINATION WHILE ON FABHALTA

MenACWY		MenB-4C	or	MenB-FHbp
<p>2 doses at least 8 weeks apart</p> <p>Single-dose booster every 5 years if the patient is still at increased risk (while on treatment)</p>	+	<p>2 doses at least 1 month apart</p> <p>Single-dose booster 1 year after primary series and every 2 to 3 years thereafter if the patient is still at increased risk (while on treatment)</p>		<p>3 doses at 0, 1 to 2, and 6 months*</p> <p>Single-dose booster 1 year after primary series and every 2 to 3 years thereafter if the patient is still at increased risk (while on treatment)</p>

Note: MenABCWY (Menactra[®], Menveo[®], MenQuadfi[®]) vaccine may be used when both MenACWY and MenB are indicated at the same visit. MenB-4C (Bexsero[®]) and MenB-FHbp (Trumenba[®]) are not interchangeable (use same product for all doses in series).^{3,4}

*If Dose 2 was administered at least 6 months after Dose 1, then Dose 3 is not needed. If Dose 3 is administered earlier than 4 months after Dose 2, then Dose 4 should be administered at least 4 months after Dose 3. MenACWY, serogroups A, C, W, and Y meningococcal; MenB, serogroup B meningococcal. The brand names mentioned above are the property of their respective trademark owners.

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Serious Infections Caused by Encapsulated Bacteria (continued)

The benefits and risks of treatment with FABHALTA, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by encapsulated bacteria.

Please [click here](#) for additional Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and Medication Guide.



A dedicated team for you and your patients

Novartis Patient Support is a comprehensive program that offers assistance to health care professionals and patients for getting started on FABHALTA. Support is available through a dedicated Novartis Patient Support team to help patients starting on FABHALTA.

Novartis Patient Support can help support your patients every step of the way



Insurance support



Financial support



Vaccination support

Our dedicated Novartis Patient Support team offers support to help your patients locate vaccinations.



Ongoing support

Vaccination support for your patients getting started on FABHALTA

- Our dedicated Novartis Patient Support team offers support to help your patients locate vaccinations
- You can opt-in to Vaccination Support on the FABHALTA (iptacopan) Start Form to further understand what your patient may be eligible for with a dedicated Novartis Patient Support team
- Vaccination Support T&Cs Limitations Apply. Please contact Novartis Patient Support at 1-833-99FABHA (1-833-993-2242) Monday through Friday, 8:00 AM-8:00 PM ET, excluding holidays for more information

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Serious Infections Caused by Encapsulated Bacteria (continued)

- Vaccination does not eliminate the risk of serious encapsulated bacterial infections, despite development of antibodies following vaccination. Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if they occur. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of FABHALTA in patients who are undergoing treatment for serious infections.

Please [click here](#) for additional Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and Medication Guide.



3 steps for getting patients started with Novartis Patient Support

How to enroll:



Download the
Start Form at
www.FABHALTA.com



Complete the Start
Form, capture consent,
and submit



Call us at
1-833-99FABHA
(1-833-993-2242)

Questions?

For more information, call Novartis Patient Support at 1-833-99FABHA (1-833-993-2242), Monday through Friday, 8:00 AM-8:00 PM ET.

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

FABHALTA REMS

- FABHALTA is available only through a restricted program under a REMS called FABHALTA REMS, because of the risk of serious infections caused by encapsulated bacteria.

Please [click here](#) for additional Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and Medication Guide.

 **FABHALTA**[®]
(iptacopan) 200 mg capsules



Insurance support and financial support

Your dedicated Novartis Patient Support team will work with you to help identify financial support options.

Bridge Program

Your patients may be eligible for up to 12 months of FABHALTA (iptacopan) for free while coverage is pursued.

- Limitations apply. Patients with commercial insurance, a valid prescription for FABHALTA, and a denial of insurance coverage based on a prior authorization requirement may receive a monthly maintenance dose for up to 12 months or until insurance coverage approval, whichever occurs first
- Not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state program, or where prohibited by law. A prior authorization and/or appeal of coverage denial must be submitted within 90 days to remain in the program
- No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Additional restrictions may apply. Novartis reserves the right to rescind, revoke, or amend this Program without notice

Co-Pay Plus

Inform your eligible patients about Co-Pay Plus. Privately insured patients may pay as little as \$0 for FABHALTA.

- Limitations apply. Patients with commercial insurance coverage for FABHALTA may receive up to \$20,000 in annual co-pay benefits for the cost of FABHALTA and up to \$1,000 for qualifying vaccination costs (excluding administrative fees). Patient is responsible for any costs once limit is reached in a calendar year
- Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles
- Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program
- Valid only in the United States, Puerto Rico, and select territories. Void where prohibited by law. Additional restrictions may apply. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

FABHALTA REMS (continued)

- Under the FABHALTA REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risks, signs, and symptoms of serious infections caused by encapsulated bacteria, provide patients with the REMS educational materials, ensure patients are vaccinated against encapsulated bacteria, prescribe antibacterial drug prophylaxis if patients' vaccine status is not up to date and treatment must be started urgently, provide instructions to always carry the Patient Safety Card during treatment and for 2 weeks following last dose of FABHALTA.
- Further information is available by telephone: 1-833-993-2242 or online at www.FABHALTA-REMS.com.

Please [click here](#) for additional Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and Medication Guide.





Ongoing support

A dedicated Novartis Patient Support team and educational resources to help your patients get started on treatment and support them along the way.

Novartis Patient Support

Novartis Patient Support provides patients with ongoing help to start, stay, and save on their FABHALTA treatment plan, including:

- Information on financial support options
- Help navigating health care changes
- Tips for setting up a routine that can help patients stay on track with their medication dosing
- Resources about living with PNH, taking FABHALTA, and finding supportive communities
- Support to answer lifestyle questions

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Monitoring of PNH Manifestations after FABHALTA Discontinuation

- After discontinuing FABHALTA, closely monitor patients for at least 2 weeks after the last dose for signs and symptoms of hemolysis. These signs include elevated lactate dehydrogenase (LDH) levels along with sudden decrease in hemoglobin or PNH clone size, fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (such as thrombosis, stroke, and myocardial infarction), dysphagia, or erectile dysfunction. If discontinuation of FABHALTA is necessary, consider alternative therapy.
- If hemolysis occurs after discontinuation of FABHALTA, consider restarting treatment with FABHALTA, if appropriate, or initiating another treatment for PNH.

Please [click here](#) for additional Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and Medication Guide.



Prescribing FABHALTA through a limited network of specialty pharmacies

Once you are ready to prescribe FABHALTA, inform your patient which specialty pharmacy will be dispensing their FABHALTA prescription, and tell them to expect a phone call to arrange delivery of their prescription. Pharmacies that dispense FABHALTA must be certified in the FABHALTA REMS and must verify that prescribers are certified.¹



Onco360®

- WEBSITE www.onco360.com
- PHONE 1-877-662-6633
- FAX 1-877-662-6355
- HOURS OF OPERATION 24/7



Biologics by McKesson

- WEBSITE biologics.mckesson.com
- PHONE 1-800-850-4306
- FAX 1-800-823-4506
- HOURS OF OPERATION 24/7

Novartis does not recommend or require the use of any particular pharmacy.

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Hyperlipidemia

- FABHALTA increases total cholesterol, LDL-cholesterol, and serum triglycerides during PNH clinical trials. Some patients required cholesterol lowering medications.
- Of 88 FABHALTA treated patients who had normal total cholesterol at baseline, 31 developed grade 1 hypercholesterolemia during the randomization or core treatment period and 1 patient worsened from baseline grade 1 to grade 2.
- Of 96 FABHALTA treated patients with LDL-cholesterol \leq 130mg/dL at baseline during the randomization or core treatment period, 14 patients developed LDL-cholesterol > 130-160mg /dL, 6 patients developed LDL-cholesterol > 160-190mg /dL and 4 patients developed LDL-cholesterol > 190mg /dL.
- Of 89 FABHALTA treated patients with normal triglycerides during the randomization or core treatment period, 22 patients developed grade 1 elevated triglycerides. Three patients experienced an increase in triglycerides from grade 1 to grade 2.
- Monitor serum lipid parameters periodically during treatment with FABHALTA and initiate cholesterol-lowering medications, if indicated.

Please [click here](#) for additional Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and Medication Guide.



Indication and Important Safety Information

INDICATION

FABHALTA is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA

FABHALTA, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

- Complete or update vaccinations for encapsulated bacteria at least 2 weeks prior to the first dose of FABHALTA, unless the risks of delaying therapy with FABHALTA outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor.
- Patients receiving FABHALTA are at increased risk for invasive disease caused by encapsulated bacteria, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious infections and evaluate immediately if infection is suspected.

Because of the risk of serious infections caused by encapsulated bacteria, FABHALTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the FABHALTA REMS.

CONTRAINDICATIONS

- Patients with serious hypersensitivity to FABHALTA or any of the excipients.
- For initiation in patients with unresolved serious infection caused by encapsulated bacteria, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, or *Haemophilus influenzae* type B.

WARNINGS AND PRECAUTIONS

Serious Infections Caused by Encapsulated Bacteria

- FABHALTA, a complement inhibitor, increases a patient's susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including *Streptococcus pneumoniae*, *Neisseria meningitidis* (caused by any serogroup, including non-groupable strains), and *Haemophilus influenzae* type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of FABHALTA is contraindicated in patients with unresolved serious infections caused by encapsulated bacteria.
- Complete or update vaccination against encapsulated bacteria at least 2 weeks prior to the start of FABHALTA, according to the current ACIP recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with FABHALTA. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent FABHALTA therapy is indicated in a patient who is not up to date with vaccines against encapsulated bacteria according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible. The benefits and risks of treatment with FABHALTA, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by encapsulated bacteria.
- Vaccination does not eliminate the risk of serious encapsulated bacterial infections, despite development of antibodies following vaccination. Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if they occur. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of FABHALTA in patients who are undergoing treatment for serious infections.

Please [click here](#) for additional Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and Medication Guide.



Important Safety Information (continued)

WARNINGS AND PRECAUTIONS (continued)

FABHALTA REMS

- FABHALTA is available only through a restricted program under a REMS called FABHALTA REMS, because of the risk of serious infections caused by encapsulated bacteria.
- Under the FABHALTA REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risks, signs, and symptoms of serious infections caused by encapsulated bacteria, provide patients with the REMS educational materials, ensure patients are vaccinated against encapsulated bacteria, prescribe antibacterial drug prophylaxis if patients' vaccine status is not up to date and treatment must be started urgently, provide instructions to always carry the Patient Safety Card during treatment and for 2 weeks following last dose of FABHALTA.
- Further information is available by telephone: 1-833-993-2242 or online at www.FABHALTA-REMS.com.

Monitoring of PNH Manifestations after FABHALTA Discontinuation

- After discontinuing FABHALTA, closely monitor patients for at least 2 weeks after the last dose for signs and symptoms of hemolysis. These signs include elevated lactate dehydrogenase (LDH) levels along with sudden decrease in hemoglobin or PNH clone size, fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (such as thrombosis, stroke, and myocardial infarction), dysphagia, or erectile dysfunction. If discontinuation of FABHALTA is necessary, consider alternative therapy.
- If hemolysis occurs after discontinuation of FABHALTA, consider restarting treatment with FABHALTA, if appropriate, or initiating another treatment for PNH.

Hyperlipidemia

- FABHALTA increases total cholesterol, LDL-cholesterol, and serum triglycerides during PNH clinical trials. Some patients required cholesterol lowering medications.
- Of 88 FABHALTA treated patients who had normal total cholesterol at baseline, 31 developed grade 1 hypercholesterolemia during the randomization or core treatment period and 1 patient worsened from baseline grade 1 to grade 2.
- Of 96 FABHALTA treated patients with LDL-cholesterol \leq 130mg/dL at baseline during the randomization or core treatment period, 14 patients developed LDL-cholesterol > 130-160mg /dL, 6 patients developed LDL-cholesterol > 160-190mg /dL and 4 patients developed LDL-cholesterol > 190mg /dL.
- Of 89 FABHALTA treated patients with normal triglycerides during the randomization or core treatment period, 22 patients developed grade 1 elevated triglycerides. Three patients experienced an increase in triglycerides from grade 1 to grade 2.
- Monitor serum lipid parameters periodically during treatment with FABHALTA and initiate cholesterol-lowering medications, if indicated.

ADVERSE REACTIONS

- The most common adverse reactions (\geq 10%) in adults with PNH receiving FABHALTA were headache, nasopharyngitis, diarrhea, abdominal pain, bacterial infection, viral infection, nausea, and rash.

DRUG INTERACTIONS

- Concomitant use of CYP2C8 inducers (eg, rifampin) may decrease iptacopan exposure, which may result in loss of or reduced efficacy of FABHALTA. Monitor the clinical response and discontinue use of the CYP2C8 inducer if loss of efficacy of FABHALTA is evident.
- Concomitant use of strong CYP2C8 inhibitors (eg, gemfibrozil) may increase iptacopan exposure, which may result in increased risk for adverse reactions with FABHALTA. Coadministration with a strong CYP2C8 inhibitor is not recommended.

USE IN SPECIFIC POPULATIONS

- Because of the potential for serious adverse reactions in a breastfed child, breastfeeding should be discontinued during treatment and for 5 days after the final dose.
- FABHALTA is not recommended in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²) with or without hemodialysis. No dose adjustment is required in patients with mild (eGFR 60 to < 90 mL/min/1.73 m²) or moderate (eGFR 30 to < 60 mL/min/1.73 m²) renal impairment.
- FABHALTA is not recommended in patients with severe hepatic impairment (Child-Pugh class C). No dose adjustment is required for patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment.

Please [click here](#) for full Prescribing Information, including Boxed WARNING and Medication Guide.



START NOW WITH



FABHALTA[®]

(iptacopan) 200 mg capsules

Please [click here](#) for Important Safety Information. Please [click here](#) for full Prescribing Information, including Boxed WARNING and Medication Guide.

References: 1. Fabhalta. Prescribing information. Novartis Pharmaceuticals Corp. 2. Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal vaccine for adults aged ≥ 19 years: recommendations of the Advisory Committee on Immunization Practices, United States, 2023. *MMWR Recomm Rep.* 2023;72(3):1-39. Accessed November 15, 2023. doi:10.15585/mmwr.rr7203a1 3. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. *MMWR Recomm Rep.* 2020;69(9):1-41. Accessed November 15, 2023. doi:10.15585/mmwr.rr6909a1 4. Advisory Committee on Immunization Practices (ACIP). ACIP recommendations: recent meeting recommendations. Published October 25-26, 2023. Accessed November 9, 2023. <https://www.cdc.gov/vaccines/acip/recommendations.html#meeting-recommendations>

FABHALTA and the FABHALTA logo are registered trademarks of Novartis AG.



Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2024 Novartis

3/24

418504



GETTING REMS
CERTIFIED

VACCINATION
REQUIREMENTS

SUPPORT

PRESCRIBING
FABHALTA

IMPORTANT SAFETY
INFORMATION